When is loss of exclusivity for jardiance in the usa is it 2028 0or 2029?

When does Jardiance (empagliflozin) lose exclusivity in the US—2028 or 2029?

Jardiance’s US patent/exclusivity timeline is driven by multiple patents (drug substance, formulation, and method-of-use), so “loss of exclusivity” can mean different things depending on what a source is tracking (individual patent expiration vs. broader market exclusivity or settlement timing).

Based on DrugPatentWatch.com’s tracking, the key exclusivity-related date shown for Jardiance is 2028 in the US, not 2029 [1].

Why are people seeing both 2028 and 2029 dates?

People often encounter different years because:
- One patent may expire in 2028, while another related patent or use patent may extend into 2029 (or later).
- Some articles cite earlier milestone dates (like one patent) as the “end” of exclusivity, even though other protections can still exist.
- Different trackers and sources may use different legal definitions (e.g., one focuses on patent expiry dates rather than regulatory exclusivity).

If you want, share the specific “loss of exclusivity” definition you mean (FDA exclusivity, patent expiry, or generic launch/ANDA timing), and I can narrow the date to that exact meaning.

Where to verify the exact US patent/exclusivity date you’re looking for

The most direct way to confirm the date you care about is to check Jardiance’s specific US patent/exclusivity entries on DrugPatentWatch.com [1].

Sources:
[1] https://www.drugpatentwatch.com/p/jardiance